To gain insights on the diverse practice patterns and treatment pathways for prostate cancer
(PC) in India, the Urological Cancer Foundation convened the first Indian survey to discuss …

Background Research overlap and duplication is a recognised problem in the context of
both pairwise and network systematic reviews and meta-analyses. As a case study, we …

Background Both Docetaxel (DOC) and Abiraterone (ABI) improve the survival of men with
metastatic, castration sensitive prostate cancer (mCSPC). However, the outcome among …

Metastatic prostate cancer is a heterogeneous disease entity. Men without prior androgen
deprivation therapy exposure are termed metastatic castration sensitive prostate cancer …

We analyzed the treatment outcome and toxicity of prostate-specific membrane antigen–
targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer …

SUMMARY LATITUDE was a multicenter, randomized, double-blind, phase 3 trial on high-
risk metastatic castration-sensitive prostate cancer (mCSPC).[1] The inclusion criteria were …

SUMMARY Sathianathen et al.[1] in their systematic review and network meta-analysis,
published in the European Urology 2020, compared the efficacy of combination therapies in …

Background Research overlap and duplication is a recognised problem in the context of
both pairwise and network systematic reviews. We carried out a systematic review to identify …

Cancer is a disease that still affects many people's lives, despite the significant progress that
scientists have made in understanding the disease mechanisms. Drug repurposing, which is …

Prostatakarzinome (PCA), die trotz laufender primärer Androgen ablationstherapie (ADT)
und niedriger SerumTestosteronwerte ein progredientes Wachstum aufweisen, bezeichnet …